Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | PDE6D | O43924 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410623 | 1.00 | ADORA2A (0.49) | ADORA2AADORA2BPKMCSNK2A2CSNK2B | |
| SCHEMBL19559321 | 0.80 | TSPO (0.50) | — | |
| SCHEMBL14689614 | 0.79 | EGFR (0.48) | PKMTDP1CA12CA1CA2 | |
| SCHEMBL16709351 | 0.79 | EGFR (0.48) | PKMTDP1CA12CA1CA2 | |
| SCHEMBL12960753 | 0.73 | ADORA2A (0.58) | ADORA2AADORA2BPKMCSNK2A2CSNK2B | |
| SCHEMBL1082044 | 0.73 | ADORA2A (0.58) | ADORA2AADORA2BPKMCSNK2A2CSNK2B | |
| SCHEMBL19547481 | 0.72 | TSPO (0.58) | — | |
| SCHEMBL18088453 | 0.72 | OPRM1 (0.50) | PKMF2PRSS1PRSS2PRSS3 | |
| SCHEMBL18721926 | 0.71 | TSPO (0.57) | — | |
| SCHEMBL18736481 | 0.71 | TDP1 (0.54) | ADORA2AADORA2BPKMCSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183011-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180127367-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2018-05-10 | — | — | US | disclosed |
| US-9962368-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-05-08 | — | — | US | disclosed |
| US-9884820-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-02-06 | — | — | US | disclosed |
| EP-2590647-B1 | PRO-NEUROGENIC COMPOUNDS | UNIV TEXAS (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20170157092-A1 | Anti-depression Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-08 | — | — | US | disclosed |
| US-9616048-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160362372-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-12-15 | — | — | US | disclosed |
| US-20160362373-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-12-15 | — | — | US | disclosed |
| US-9446042-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-09-20 | — | — | US | disclosed |
| WO-2014031125-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20130190339-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184301-A1 | Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184271-A1 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184300-A1 | Methods of Treating Traumatic Brain Injury Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-02-14 | — | — | US | disclosed |
| US-8362277-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2012006419-A2 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20110003836-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184301-A1 | Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds | BDNF, GAP43, DCX | ADORA2A 632/4885ADORA2B 841/4885PKM 2044/4885 |
| US-20130184271-A1 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds | BDNF, GAP43, NES | ADORA2A 2508/4885ADORA2B 3228/4885PKM 3154/4885 |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BDNF, GAP43, DCX | ADORA2A 2455/4885ADORA2B 3133/4885PKM 3688/4885 |
| US-20180127367-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | ADORA2A 2455/4885ADORA2B 3133/4885PKM 3688/4885 |
| US-20130190339-A1 | Pro-Neurogenic Compounds | DCX, GAP43, BDNF | ADORA2A 1532/4885ADORA2B 1965/4885PKM 2821/4885 |
| US-10183011-B2 | Anti-depression compounds | BDNF, DCX, GAP43 | ADORA2A 1940/4885ADORA2B 2726/4885PKM 3619/4885 |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | ADORA2A 2455/4885ADORA2B 3133/4885PKM 3688/4885 |
| US-20160362373-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | ADORA2A 2455/4885ADORA2B 3133/4885PKM 3688/4885 |
| US-20110003836-A1 | Pro-Neurogenic Compounds | DCX, GAP43, BDNF | ADORA2A 1500/4885ADORA2B 1880/4885PKM 2867/4885 |
| US-20130184300-A1 | Methods of Treating Traumatic Brain Injury Using Pro-Neurogenic Compounds | DCX, GAP43, BDNF | ADORA2A 618/4885ADORA2B 766/4885PKM 2363/4885 |
| US-20160362372-A1 | PRO-NEUROGENIC COMPOUNDS | DCX, GAP43, BDNF | ADORA2A 1532/4885ADORA2B 1965/4885PKM 2821/4885 |
| US-20170157092-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | ADORA2A 1940/4885ADORA2B 2726/4885PKM 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.